Table 2.
CD86 and HLA-DR expression levels on DCs.
| Baseline | 4 Weeks | |||||
|---|---|---|---|---|---|---|
| Group | n | Mean (SE) | Mean (SE) | p Value | ||
| pDCs | CD86 MFI | Placebo | 47 | 1732.0 (74.7) | 1665.9 (48.4) | 0.037 |
| MCC1849 | 48 | 1674.5 (51.2) | 1764.6 (53.4) | |||
| pDCs | HLA-DR MFI | Placebo | 47 | 76,190.9 (3667.8) | 80,225.3 (3925.4) * | 0.933 |
| MCC1849 | 48 | 78,657.8 (4191.1) | 82,813.9 (4427.6) * | |||
| mDCs | CD86 MFI | Placebo | 47 | 8512.8 (289.9) | 9376.2 (184.3) * | 0.243 |
| MCC1849 | 48 | 8505.0 (289.6) | 9094.3 (192.2) * | |||
| mDCs | HLA-DR MFI | Placebo | 47 | 150,305.9 (6179.8) | 143,595.4 (7363.0) | 0.358 |
| MCC1849 | 48 | 145,741.5 (5594.2) | 145,990.5 (6663.1) |
p value, estimated by analysis of covariance (ANCOVA) adjusted for baseline values. * p value < 0.05, comparison between baseline and 4 weeks by paired t-test.